BioSpace News Archive

Pictured: Aerial view of the San Francisco skyline

Now Hiring

Looking for a biopharma job in San Francisco or South San Francisco? Check out the BioSpace list of eight companies hiring life sciences professionals like you.

August 28, 2025

·

1 min read

·

Chantal Dresner

Obesity

Novo Seeks RNA Approach to Obesity, Diabetes With $550M Replicate Deal

Novo Nordisk has brought on other cardiometabolic collaborators this year, including United Laboratories International and Deep Apple Therapeutics.

August 28, 2025

·

1 min read

·

Tristan Manalac

Illustration showing large scissors cutting employees in half

Layoffs

Exelixis Lays Off 130 as Pennsylvania Site Closes Down

Exelixis is looking at the possibility of relocating some of the eliminated Pennsylvania roles to its headquarters in Alameda, California, according to a company spokesperson.

August 28, 2025

·

2 min read

·

Tristan Manalac

Susan Monarez speaking to a senator at her confirmation hearing as CDC director

Policy

Monarez Fired From Top CDC Spot Following Friction Over New COVID-19 Vaccine Policy

The CDC director—the first to be confirmed by the Senate under new legislation—has been ousted after less than a month following internal unrest regarding new, more restrictive approvals for updated COVID-19 vaccines, according to multiple sources.

August 28, 2025

·

3 min read

·

Heather McKenzie

Illustration of businessman with question mark head on colorful comic-style background

Interviews

Job Interviews That Needed a Do-Over

Sometimes, job interviews stand out for all the wrong reasons, including odd settings, off-topic topics and questionable decorum. BioSpace collected several stories that highlight biopharma professionals’ strangest experiences as they pursued employment.

August 28, 2025

·

4 min read

·

Angela Gabriel

vector illustration arrows miss the target board, concept of lost in focus, failure, fail, mistake

Alzheimer’s

Prothena’s Alzheimer’s Drug Comes With Familiar Side Effect in Phase I Test

In another blow to Prothena’s neurodegenerative disease portfolio, anti-amyloid candidate PRX012 has run into the same problem that larger peers Biogen and Eli Lilly have battled: high rates of swelling in the brain.

August 28, 2025

·

2 min read

·

Annalee Armstrong